Carol A Langford1, Paul A Monach2, Ulrich Specks3, Philip Seo4, David Cuthbertson5, Carol A McAlear6, Steven R Ytterberg3, Gary S Hoffman1, Jeffrey P Krischer5, Peter A Merkel7. 1. Cleveland Clinic, Cleveland, Ohio, USA. 2. Boston University, Boston, Massachusetts, USA. 3. Mayo Clinic, Rochester, Minnesota, USA. 4. John Hopkins University, Baltimore, Maryland, USA. 5. University of South Florida, Tampa, Florida, USA. 6. University of Pennsylvania, Philadelphia, Pennsylvania, USA. 7. Boston University, Boston, Massachusetts, USA University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abstract
OBJECTIVES: To determine the safety and efficacy of abatacept in non-severe relapsing granulomatosis with polyangiitis (Wegener's)(GPA). METHODS: An open-label trial of intravenous abatacept was conducted in 20 patients with non-severe relapsing GPA. Prednisone up to 30 mg daily was permitted within the first 2 months, and patients on methotrexate, azathioprine, or mycophenolate mofetil continued these agents. Patients remained on study until common closing or early termination. RESULTS: Of the 20 patients, 18 (90%) had disease improvement, 16 (80%) achieved remission (BVAS/WG=0) at a median of 1.9 months, and 14 (70%) reached common closing. Six patients (30%) met criteria for early termination due to increased disease activity; 3 of 6 achieved remission and relapsed at a median of 8.6 months. The median duration of remission before common closing was 14.4 months, with the median duration of time on study for all patients being 12.3 months (range 2-35 months). Eleven of the 15 (73%) patients on prednisone reached 0 mg. Nine severe adverse events occurred in 7 patients, including 7 infections that were successfully treated. CONCLUSIONS: In this study of patients with non-severe relapsing GPA, abatacept was well tolerated and was associated with a high frequency of disease remission and prednisone discontinuation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVES: To determine the safety and efficacy of abatacept in non-severe relapsing granulomatosis with polyangiitis (Wegener's)(GPA). METHODS: An open-label trial of intravenous abatacept was conducted in 20 patients with non-severe relapsing GPA. Prednisone up to 30 mg daily was permitted within the first 2 months, and patients on methotrexate, azathioprine, or mycophenolate mofetil continued these agents. Patients remained on study until common closing or early termination. RESULTS: Of the 20 patients, 18 (90%) had disease improvement, 16 (80%) achieved remission (BVAS/WG=0) at a median of 1.9 months, and 14 (70%) reached common closing. Six patients (30%) met criteria for early termination due to increased disease activity; 3 of 6 achieved remission and relapsed at a median of 8.6 months. The median duration of remission before common closing was 14.4 months, with the median duration of time on study for all patients being 12.3 months (range 2-35 months). Eleven of the 15 (73%) patients on prednisone reached 0 mg. Nine severe adverse events occurred in 7 patients, including 7 infections that were successfully treated. CONCLUSIONS: In this study of patients with non-severe relapsing GPA, abatacept was well tolerated and was associated with a high frequency of disease remission and prednisone discontinuation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Entities:
Keywords:
Granulomatosis with polyangiitis; Systemic vasculitis; Treatment
Authors: J H Stone; G S Hoffman; P A Merkel; Y I Min; M L Uhlfelder; D B Hellmann; U Specks; N B Allen; J C Davis; R F Spiera; L H Calabrese; F M Wigley; N Maiden; R M Valente; J L Niles; K H Fye; J W McCune; E W St Clair; R A Luqmani Journal: Arthritis Rheum Date: 2001-04
Authors: Julia U Holle; Wolfgang L Gross; Ute Latza; Bernhard Nölle; Petra Ambrosch; Martin Heller; Regina Fertmann; Eva Reinhold-Keller Journal: Arthritis Rheum Date: 2011-01
Authors: David Jayne; Niels Rasmussen; Konrad Andrassy; Paul Bacon; Jan Willem Cohen Tervaert; Jolanta Dadoniené; Agneta Ekstrand; Gill Gaskin; Gina Gregorini; Kirsten de Groot; Wolfgang Gross; E Christiaan Hagen; Eduardo Mirapeix; Erna Pettersson; Carl Siegert; Alberto Sinico; Vladimir Tesar; Kerstin Westman; Charles Pusey Journal: N Engl J Med Date: 2003-07-03 Impact factor: 91.245
Authors: G S Hoffman; G S Kerr; R Y Leavitt; C W Hallahan; R S Lebovics; W D Travis; M Rottem; A S Fauci Journal: Ann Intern Med Date: 1992-03-15 Impact factor: 25.391
Authors: Dinesh Khanna; Cathie Spino; Sindhu Johnson; Lorinda Chung; Michael L Whitfield; Christopher P Denton; Veronica Berrocal; Jennifer Franks; Bhavan Mehta; Jerry Molitor; Virginia D Steen; Robert Lafyatis; Robert W Simms; Anna Gill; Suzanne Kafaja; Tracy M Frech; Vivien Hsu; Robyn T Domsic; Janet E Pope; Jessica K Gordon; Maureen D Mayes; Elena Schiopu; Amber Young; Nora Sandorfi; Jane Park; Faye N Hant; Elana J Bernstein; Soumya Chatterjee; Flavia V Castelino; Ali Ajam; Yue Wang; Tammara Wood; Yannick Allanore; Marco Matucci-Cerinic; Oliver Distler; Ora Singer; Erica Bush; David A Fox; Daniel E Furst Journal: Arthritis Rheumatol Date: 2019-12-10 Impact factor: 10.995